 |
 |
GEO help: Mouse over screen elements for information. |
|
| Status |
Public on Jul 20, 2012 |
| Title |
AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by array
|
| Summary |
Purpose: Deregulated phosphatidylinositol 3-kinase pathway signaling through AGC kinases including AKT, p70S6 kinase, PKA, SGK and Rho kinase, is a key driver of multiple cancers. The simultaneous inhibition of multiple AGC kinases may increase antitumor activity and minimize clinical resistance compared with a single pathway component. Experimental Design: We investigated the detailed pharmacology and antitumor activity of the novel clinical drug candidate AT13148, an oral ATP-competitive multi-AGC kinase inhibitor. Gene expression microarray studies were undertaken to characterize the molecular mechanisms of action of AT13148. Results: AT13148 caused substantial blockade of AKT, p70S6K, PKA, ROCK and SGK substrate phosphorylation and induced apoptosis in a concentration and time-dependent manner in cancer cells with clinically relevant genetic defects in vitro and in vivo. Antitumor efficacy in HER2-positive, PIK3CA-mutant BT474 breast, PTEN-deficient PC3 human prostate cancer and PTEN-deficient MES-SA uterine tumor xenografts was demonstrated. We show for the first time that induction of AKT phosphorylation at serine 473 by AT13148, as reported for other ATP-competitive inhibitors of AKT, is not a therapeutically relevant reactivation step. Gene expression studies showed that AT13148 has a predominant effect on apoptosis genes, whereas the selective AKT inhibitor CCT128930 modulates cell cycle genes. Induction of upstream regulators including IRS2 and PIK3IP1 due to compensatory feedback loops was observed. Conclusions: The clinical candidate AT13148 is a novel oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity, which demonstrates a distinct mechanism of action from other AKT inhibitors. AT13148 will now be assessed in a first-in-human Phase I trial.
|
| |
|
| Overall design |
The PTEN-deficient U87MG glioblastoma cell line was treated for 6 hours with vehicle control (DMSO) or to different concentrations of AT13148 and CCT128930 (0.1uM, 1xGI50 and 3XGI50).
|
| |
|
| Contributor(s) |
Yap TA, Walton MI, Grimshaw KM, te Poele RH, Eve PD, Valenti M, De Haven Brandon A, Martins V, Zetterlund A, Heaton SP, Heinzmann K, Jones PS, Feltell R, Reule M, Woodhead SJ, Davies TG, Lyons JF, Raynaud FI, Eccles SA, Workman P, Thompson NT, Garrett MD |
| Citation(s) |
22781553 |
| |
| Submission date |
May 16, 2012 |
| Last update date |
Jan 23, 2019 |
| Contact name |
Robert te Poele |
| E-mail(s) |
robert.te-poele@icr.ac.uk
|
| Phone |
00442087224319
|
| Organization name |
The Institute of Cancer Research
|
| Department |
Cancer Reserach UK Unit for Cancer Therapeutics
|
| Lab |
Signal Transduction and Molecular Pharmacology Team
|
| Street address |
15 Cotswold Road
|
| City |
Sutton |
| State/province |
Surrey |
| ZIP/Postal code |
SM2 5NG |
| Country |
United Kingdom |
| |
|
| Platforms (1) |
| GPL6480 |
Agilent-014850 Whole Human Genome Microarray 4x44K G4112F (Probe Name version) |
|
| Samples (28)
|
|
| Relations |
| BioProject |
PRJNA167208 |
| Supplementary file |
Size |
Download |
File type/resource |
| GSE38008_RAW.tar |
291.4 Mb |
(http)(custom) |
TAR (of TXT) |
| Processed data included within Sample table |
|
|
|
|
 |
Less...
More...